Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide

Abstract Background Glioblastoma (GB) is the most aggressive of all primary brain tumours and due to its highly invasive nature, surgical resection is nearly impossible. Patients typically rely on radiotherapy with concurrent temozolomide (TMZ) treatment and face a median survival of ~ 14 months. Al...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Craig A. Vincent, Itzel Nissen, Soran Dakhel, Andreas Hörnblad, Silvia Remeseiro
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2023-10-01
Edice:	BMC Cancer
Témata:	EGFR Enhancer Glioblastoma Epigenomic perturbation CRISPR/Cas9
On-line přístup:	https://doi.org/10.1186/s12885-023-11418-9
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!